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ABSTRACT 
Fenretinide remains the most investigated retinoid compound for the prevention of cancer. Its 
clinical use remains a genuine possibility due to a favourable toxicological profile and 
accumulation in fatty tissues. Like other well-characterised pharmacological therapies, 
Fenretinide has been shown to affect multiple signalling pathways. Recent findings have 
discovered additional beneficial properties the synthetic retinoid was not intentionally 
designed for, including the prevention of high-fat diet-induced obesity and insulin resistance. 
These preclinical findings in rodents are timely since obesity has reached pandemic 
proportions and safe effective therapeutics are severely lacking. Recent investigations have 
proposed various mechanisms of action for the beneficial effects of Fenretinide. This review 
covers the current knowledge about Fenretinide‟s use as a therapy for cancer and potential to 
treat obesity, insulin resistance and glucose intolerance. An overview of the signalling 
pathways manipulated by Fenretinide including retinoid homeostasis, reactive oxygen species 
generation and inhibition of ceramide synthesis will be presented and insights into apoptosis 
and/or autophagy induction by Fenretinide will also be discussed. The largely unexplored area 
of Fenretinide metabolites as alternative therapeutic options and how these may be relevant 
will also be presented. Fenretinide shows great promise but unfortunately evidence is lacking 
from clinical trials on Fenretinide‟s effectiveness in humans. Finally we identify what action 
can be taken to further progress the investigation of this extremely important retinoid. 
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1. Introduction. 
 Obesity, the condition of being overweight or to carry excess body fat is ubiquitous in 
today‟s society and is often stated as having reached epidemic status. Systematic analysis of 
health examination surveys and epidemiological studies has estimated that worldwide, more 
than 1.46 billion adults were overweight with a body mass index (BMI) of ≥25 kg/m2  in the 
year 2008 [1]. Moreover, around a third of these individuals were classed as obese with a 
BMI of ≥30 kg/m2 [1]. Of greater concern, obesity poses additional serious detrimental health 
consequences associated with perturbations to metabolic homeostasis. These include, but are 
not limited to, chronic diseases such as type II diabetes [2], cardiovascular disease [3] and the 
development of certain types of cancers [4]. Moreover, despite extensive pre-clinical and 
clinical research into these complex diseases, they continue to be the major causes of death 
worldwide. It is therefore imperative that efforts are made to reduce the levels of obesity and 
obesity-associated metabolic disturbances that are currently observed today in both the 
developed and developing world.  
Unfortunately, education through the promotion of healthy lifestyles along with well-
balanced diets appears to have had little impact on reversing the ever-expanding numbers of 
overweight and obese individuals. Thus, like the approach to target cancer with 
pharmaceutical therapy and/or prevention, an alternative approach to combat levels of obesity 
would be through the development of safe and effective pharmacological treatments. Despite 
the scale of the present situation, unfortunately very few therapeutic options are available [5]. 
More drugs are approved for the treatment of type II diabetes, however potentially dangerous 
side-effects are still encountered with their use [2,6]. Promisingly, vitamin A and its 
derivatives known as retinoids have been evaluated and used for the treatment of some types 
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of cancer and more recently, preclinical studies have suggested they may be useful for the 
prevention and/or treatment of obesity and type II diabetes.  
2. Retinol metabolism and all-trans-retinoic acid signalling. 
Vitamin A (or retinol) is the parent compound of all bioactive retinoids and is 
convertible to other natural forms through the retinol metabolism pathway. Active metabolites 
of retinol, primarily all-trans-retinoic acid (RA), act as important signalling molecules with 
the ability to induce gene expression through specific nuclear hormone receptors [7]. RA-
receptor (RAR)s form heterodimers with retinoid-X receptors (RXR)s and bind to RA-
response elements (RARE)s present in the promoters of target genes via the DNA-binding 
domain present within each receptor. As a result, the metabolism of vitamin A has been 
shown to play essential roles in the preservation of immune function, continued promotion of 
good vision and the development, growth and maintenance of multiple body tissues. 
Acquiring and maintaining a sufficient quantity of this fat soluble vitamin is therefore 
essential for life. Animals however do not have the capability to generate vitamin A via de 
novo synthesis. Vitamin A must therefore be obtained from dietary sources, stored in the liver 
and mobilised as required. 
Dietary intake of vitamin A can be achieved through the absorption of pigments 
known as carotenoids from fruits and vegetables. These pro-vitamins can then be 
enzymatically cleaved and converted to compounds with the biological activity of retinol [7]. 
Alternatively, intake can be achieved by consuming animal tissue such as liver, where pro-
vitamin A carotenoids have already been processed and stored in the form of retinyl esters. 
Although vitamin A is essential, excessive intake can be equally detrimental to life. 
Hypervitaminosis A can lead to toxicity of the liver, decreased bone mineral density and 
induce teratogenic effects in the developing embryo [7]. Additional concerns arise with the 
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use of retinoid therapy in women of child bearing age, as these compounds have the capability 
of inducing teratogenic effects in the developing conceptus. Vitamin A is a lipophilic, fat 
soluble molecule and therefore requires specific binding proteins in order to be transported in 
the circulation and within the cell. Despite this necessity, retinoid compounds are soluble in 
aqueous solutions at relatively low concentrations. For example, RA is water soluble up to 
concentrations of 210 nM at room temperature and pH 7.3 [7]. This makes retinoid 
compounds ideal morphogens. The generation of morphogen concentration gradients through 
diffusion allows for selective cellular differentiation to occur and determine tissue pattern 
during development [8]. As a result, the administration of retinoid compounds has been 
shown to provoke teratogenic effects in both animal models and humans. It has been 
suggested that chemical modification of the terminal-polar group of the retinoid molecule 
would offer a useful way to reduce toxicity but also modify activity, metabolism and tissue 
distribution of this class of compounds [9,10]. 
3. N-(4-hydroxyphenyl)retinamide; a synthetic retinoid. 
3.1. Structural and advantageous properties of N-(4-hydroxyphenyl)retinamide. 
N-(4-hydroxyphenyl)retinamide, otherwise known as 4-HPR or Fenretinide (FEN, 
used hereafter), is one such synthetic retinoid that was first synthesised in 1960s  by R.W. 
Johnson Pharmaceuticals now part of Johnson and Johnson [11]. FEN shares a similar 
chemical structure with RA however it contains an amide linked 4-hydroxyphenyl group, 
which replaces the carboxyl polar end group of RA (Fig.1.). It is the addition of this bulky 4-
hydroxyphenyl group which is thought to be responsible for a number of beneficial properties 
associated with FEN treatment, compared to alternative retinoid compounds such as RA 
Since naturally derived vitamin A compounds such as RA and retinyl-acetate 
supplemented in large doses show liver toxicity with prolonged exposure this restricts their 
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potential use as medicinal agents. FEN on the other hand displays a decreased toxicological 
profile, which may occur due to a number of reasons. Chronic retinyl-acetate treatment results 
in the deposition of retinyl esters in the liver and subsequently causes hepatic toxicity. In 
contrast, FEN does not appear to be stored in the liver of rats [11]. This may be due to the 
observation that FEN and its metabolites are preferentially stored in fatty tissues such as 
mammary gland, which has been observed in both animal models and human studies [11,12]. 
Therefore, this characteristic appears to prevent FEN treatment leading to hepatotoxic 
accumulation and is highly advantageous compared to the use of natural forms of vitamin A 
as a therapeutic option. The specific accumulation of FEN in fatty tissues is also an beneficial 
property for the prevention/treatment of breast cancer, obesity and type II diabetes [11-14]. 
Encouragingly, studies performed in rats and rabbits have revealed that when FEN 
was given orally at 20 mg/kg/day, no adverse effects were observed in either species. At 
higher doses of 125-800 mg/kg/day, FEN was deemed to be only weakly teratogenic in these 
species [15]. Studies in hamsters dosed with up to 130 mg/kg of 13-cis-N-(4-
hydroxyphenyl)retinamide also failed to induce a teratogenic response [10]. Genotoxic studies 
(the Ames mutagenicity test, a mouse lymphoma assay and a rat bone marrow cytogenetic 
assay) with FEN treatment reported all negative findings [16]. Together these results 
indicated that FEN is unable to induce point mutations or chromosomal aberrations and is 
therefore not a genotoxic compound.  
3.2 Cancer chemoprevention trials 
These desirable properties make the use of FEN as a therapeutic agent a genuine 
possibility. In agreement with this, due to the beneficial chemopreventive potential that FEN 
treatment has displayed during its early investigation in pre-clinical animal models [11], 
human clinical trials, predominantly for breast cancer chemoprevention, have demonstrated 
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that FEN is well-tolerated and compatible with long term treatment schedules [17]. In a large 
randomized trial of FEN to prevent second breast malignancy in almost 3000 women with 
early breast cancer, overall, FEN treatment for 5 years appears to have no statistically 
significant effect on the incidence of second breast malignancies of women with breast cancer 
[17].  A possible benefit was detected in premenopausal women, results that persisted in a 15-
year follow-up [17,18]. These effects are potentially through an associated lowering of 
circulating IGF-1 levels, a potent stimulator of cell growth [17]. Combination therapy with 
low dose tamoxifen also did not reduce breast cancer events compared to placebo or single 
agents alone [19]. Unfortunately, overall these trials have yielded only preliminary data and 
new untested hypotheses.  
FEN has also been widely studied in rodent bladder carcinogenesis models, where it 
has shown the highest therapeutic index among the retinoids tested, however in phase III trials 
it did not reduce the recurrence of bladder cancer in patients [20]. The lack of FEN efficacy in 
these trials has been suggested to be due to the dose used and subsequent tissue levels 
achieved, that was essentially too low to induce apoptosis, the major hypothesized mechanism 
of anti-cancer activity in cultured cells. FEN induces apoptosis in cells that are resistant to 
RA, suggesting that FEN-induced apoptosis may involve RAR–independent mechanism(s), 
such as increased generation of reactive oxygen species (ROS) and ceramide species and 
activation of stress kinases, endoplasmic reticulum (ER) stress and autophagy pathways [21]. 
However, high concentrations of FEN are required to induce apoptosis [22,23]. With this in 
mind, high doses of FEN and formulation within novel lipid matrices to improve FEN 
bioavailability and attain higher plasma concentrations have been tested in adults and in 
children with neuroblastoma with minimal toxicity [24,25]. Since higher plasma levels of 
FEN were achieved using this strategy, a phase II trial would now be recommended to further 
evaluate its anti-cancer activity. 
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4.  Mechanisms of FEN-mediated anti-cancer activity. 
Apoptosis is a physiological process of programmed cell death, is disrupted in various 
cancers and thus has been exploited as strategy to combat the disease, traditionally by 
inducing DNA damage with chemo- and radio-therapy. With an increased understanding of 
the intrinsic and extrinsic pathways of apoptosis (essentially mitochondrial mechanism and 
TRAIL-Fas-death receptor mechanism respectively) in recent years, novel approaches of 
targeting apoptosis have been tested in pre-clinical models and early phase clinical trials [26]. 
Natural retinoids like RA induce differentiation and/or cytostasis in target cells, while FEN 
can trigger apoptosis (at least in cultured cancer cells) via distinct biological effects.  
4.1 Involvement of the canonical retinoid signalling pathway. 
As a synthetic derivative of RA, it would be anticipated that similar to its natural 
counterpart, FEN would be an agonist for RARs and activate the retinoid signalling pathway. 
This however has proved to be a controversial issue. It was shown in one study that unlike 
RA, FEN bound very poorly to all three RAR isoforms [27], which may be due to the fact that 
FEN does not contain a carboxyl functional group (see Figure 1). In keeping with this 
interpretation, earlier investigations observed that FEN treatment was able to induce apoptosis 
in malignant hemopoietic cell lines, including those that were resistant to the effects of RA 
[28], implying a RAR-independent mechanism of action. Although FEN may also have RAR-
independent mechanisms of action, some of which shall be discussed shortly, a number of 
studies have been conducted which established that FEN can bind to RARs and activate 
RAREs. It was found that FEN did display binding affinity with RARs, however only at 15% 
to that observed with RA treatment [29]. This finding implied that FEN could operate in a 
RAR dependant manner, however appeared to be less potent that RA. Additional reports have 
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confirmed this finding, since FEN can induce transcription of RARs as demonstrated by 
activation RARE reporter gene assays [23,30,31]. 
FEN has the ability to bind to serum retinol binding protein (RBP4, discussed later in 
section 6) however, no binding affinity has been observed between FEN and the cellular 
retinol or cellular RA binding proteins (CRBP or CRABP) [29]. Consistent with 
transactivation assays that indicate FEN can induce transcription via RARs [23,30,31], FEN 
was found to activate the RARE in the promoter for Crbp1 and was actually observed to be a 
stronger activator than RA when in the presence of RXRγ-RARγ or RXRβ-RARγ 
heterodimers, which bind direct repeat (DR)-2 RAREs [31].  
More recently, Y-J.Y Wan and co-workers have shown that FEN-induced apoptosis in 
FEN-sensitive Huh7 liver carcinoma cells involves a RARβ-dependant interaction with 
nuclear orphan receptor Nur77 that leads to nuclear export of the two proteins [32]. Nur77 has 
been reported to relocate to mitochondria where it participates in the conversion of Bcl-2 into 
a pro-apoptotic molecule [33]. In contrast, a subsequent transcriptome analysis in Huh7 cells 
identified that FEN (unlike RA) specifically induced TRAIL-Fas-death receptor mediated 
apoptosis by increasing the expression of pro-apoptotic genes such as caspase 8 [34].  
4.2 Induction of Cyp26a1 and generation of 4-oxo-FEN 
Results from ovarian carcinoma cells also demonstrated that endogenous Crbp1 and 
Cyp26a1gene expression was elevated >20-fold when continuously treated with FEN 
compared to non-treated cells [35]. Similarly to RA, the oxidation of FEN via the induction of 
Cyp26a1 can result in the generation of polar metabolites. One metabolite, 
N-(4-hydroxyphenyl)-4-oxoretinamide (4-oxo-FEN), has been identified in both FEN treated 
ovarian carcinoma cells and plasma from patients participating in a FEN clinical trial [35]. 4-
oxo-FEN levels were also detected when RARβ and RARγ were overexpressed, indicating the 
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involvement of the canonical retinoid signalling in the generation of 4-oxo-FEN [35]. As 
observed with the parent compound FEN, 4-oxo-FEN was found to be more effective at 
inhibiting proliferation of numerous tumour cell lines [36]. Although 4-oxo-FEN is generated 
through activation of the retinoid metabolism pathway, the anti- proliferative action of 4-oxo-
FEN was proposed to be through RAR-independent mechanisms since, 4-oxo-FEN was able 
to inhibit cancer cell proliferation in both FEN-sensitive and FEN-resistant cell lines. 
Additionally, 4-oxo-FEN was observed to bind poorly to RARs and RAR antagonist 
treatment failed to prevent 4-oxo-FEN mediated cell growth inhibition [35]. Moreover, unlike 
FEN and independent of ROS generation, 4-oxo-FEN also appears to cause G2-M mitotic 
arrest through anti-microtubule activities [36]. However, there are a limited number of studies 
with FEN metabolites and thus it is not clear whether they share common or very different 
mechanisms of action with FEN. 
5. RAR-independent mechanisms of FEN-induced apoptosis 
In most cell systems, the apoptotic effect of FEN appears to be independent of RAR 
activation and involves generation of ROS and lipid second messengers [21]. Most 
consistently, antioxidants (e.g. vitamin C, N-acetylcysteine and butylated hydroxyanisole) 
have been shown to inhibit FEN-induced apoptosis. Early studies in various cancer cells 
indentified that FEN-induced apoptosis was associated with sustained-activation of mitogen 
activated protein kinase (MAPK)s JNK, p38 and ERK1/2, induction of proapoptotic 
transcription factor GADD153/CHOP and BCL-2 family member BAK and downstream 
activation of caspase-9 and caspase-3 [21]. The induction of sphingolipid second messenger 
ceramide and ganglioside GD3 by means of de novo synthesis via ceramide and GD3 
synthases and/or hydrolysis of sphingomylin and downstream activation of 12-lipoxygenase 
has also been postulated to be a mechanism of FEN-mediated induction of BAK and 
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GADD153/CHOP leading to apoptosis by Lovat, Redfern and co-workers [21]. Due to the 
constraints (maximum word and reference limits) at use in this journal for its short reviews, 
we have chosen to focus on the more recent developments in the signalling pathways 
proposed for FEN-induced apoptosis or cell survival. Earlier studies from the 1990s to mid-
2000s (as briefly mentioned in this paragraph) are well documented in the 2006 review by N. 
Hail Jnr et al. [21]. The high level of cross-talk between the multiple signalling pathways 
postulated to play a role in FEN-mediated biological effects are summarised in Fig. 2. 
5.1 Induction of pro-apoptotic BAK versus anti-apoptotic Bcl-2 
All of the pro-apoptotic effects of FEN, including ROS generation, have been shown 
to require induction of pro-apoptotic Bak in neuroblastoma cells and to be suppressed in 
cervical cancer  cells with the overexpression of anti-apoptotic Bcl-2. Thus, in a strategy to 
inhibit Bcl-2 family members in combination with FEN, Reynolds and co-workers found that 
ABT-737, a small-molecule BH3-mimetic that inhibits most proteins of the Bcl-2 family, 
could enhance FEN activity in neuroblastoma [37]. FEN in combination with  ABT-737 
induced greater mitochondrial membrane depolarization and mitochondrial cytochrome c 
release, greater activation of caspases of both the intrinsic and extrinsic pathways, greater 
activation of Bax-α, t-Bid, and Bak, and a higher level of apoptosis than either drug alone. In 
vivo, FEN with ABT-737 showed a similar anti-neuroblastoma activity in a mouse xenograft 
model of neuroblastoma. Thus, the synergistic cytotoxic effects of drug combination of FEN 
with an inhibitor of Bcl-2 family members hold great prospects and warrants future clinical 
trials. 
5.2 ROS production via mitochondrial electron transport chain 
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Since FEN-induced ROS production could be decreased in intact cells co-treated with 
rotenone or certain co-enzyme Q analogues, this implied that the turnover of complex I may 
contribute to the pro-oxidant activity of FEN [21]. State-of-the-art experimental 
methodologies utilising isolated mitochondrial preparations with respect to establishing the 
direct mitochondrial toxicity of agents like FEN, still have their limitations and may require 
additional validation in a cellular context. Consequently, the direct and/or indirect 
mitochondrial effects of FEN may be challenging to elucidate fully. However, it is certainly 
possible that FEN could promote ROS at a site associated with oxidative phosphorylation that 
is specifically required in rapidly dividing cells such as transformed cells, and not by 
disrupting oxidative phosphorylation in general which would produce far more adverse side 
effects than those commonly observed. 
Hail and co-workers recently hypothesised that dihydroorotate dehydrogenase 
(DHODH), an enzyme associated with mitochondrial electron transport and required for de 
novo pyrimidine synthesis, could be an important link between mitochondrial bioenergetics, 
cell proliferation, and sensitivity to FEN-induced ROS and apoptosis in certain transformed 
cell types [38]. In prostate and skin cancer cells the suppression of DHODH activity by 
chemical inhibition or the reduction in DHODH protein expression by RNA interference 
markedly decreased FEN-induced ROS generation and apoptosis. Conversely, colon 
carcinoma cells that lacked DHODH expression were markedly resistant to the pro-oxidant 
and cytotoxic effects of FEN. This study strongly implicates DHODH in FEN-induced ROS 
production and apoptosis.  
5.3 Dihydroceramide generation & autophagy induction 
Early studies had shown FEN-induced increases in ceramide, however analysis by 
liquid chromatography-tandem mass spectrometry (LC-MS) has determined with more 
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specificity that FEN is responsible for increased levels of dihydroceramide [39], the 
immediate precursor of ceramide. FEN was shown to inhibit dihydroceramide desaturase 
activity in cell-based and in vitro assays [40].  It was also shown in this study that RA failed 
to inhibit dihydroceramide activity, indicating that FEN acted in a RAR-independent manner 
to increase dihydroceramide levels. Kraveka and co-workers have gone on to show more 
recently that FEN (and 4-oxo-FEN) can act as a direct inhibitor of the enzyme 
dihydroceramide desaturase 1 (DES1) in vitro [41]. This enzyme is responsible for the 
desaturation of dihydroceramide, final step of de novo synthesis of ceramide lipid species 
from dihydroceramide precursors. Thus inhibition of DES1 would prevent the final step in the 
production of ceramide and lead to an accumulation of dihydroceramide.  
Further LC-MS analysis of sphingolipids in several cancer cell lines has identified that 
treatment with either FEN or 4-oxo-FEN leads to a marked increase in dihydroceramide and 
complex dihydrosphingolipids, while only 4-oxo-FEN led to a minor increase of ceramide 
species [42,43]. These findings are of considerable interest since dihydroceramides are 
thought to be biologically inert thereby they are inactive on the pathways modulated by 
ceramides, but it has recently been reported that dihydroceramides can induce autophagy in 
prostate cancer cells and cell growth inhibition with cell cycle arrest in neuroblastoma cells 
[39,40]. 
5.4 mTOR and autophagy, a cell survival mechanism. 
The mechanism(s) by which FEN can lead to the induction of autophagy and/or 
apoptotic cell death is currently unclear. Both FEN exposure and dihydroceramides 
accumulation can initiate cellular survival pathways such as the ER stress response and 
autophagy induction [39,44-46]. FEN has also been reported to inhibit the kinase activity of 
mammalian target of rapamycin (mTOR) both in vitro and in vivo [47]. This may possibly 
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occur through the direct binding of FEN to the ATP pocket of mTOR based on computer 
modelling of the crystal structure of PI3K-delta [47]. Since mTOR is a key inhibitor of 
autophagy, inhibition of mTOR by FEN may result in an increase in autophagy induction. 
Autophagy plays an important role in cell survival as its inhibition in mammalian cells 
during nutrient depletion causes apoptosis. Interestingly, the presence of 10% serum in cell 
culture media strongly abrogated FEN-mediated apoptosis [48]. Moreover, FEN treatment at 
suboptimal doses for apoptotic induction was shown to induce autophagy and proposed to act 
as survival advantage to malignant glioma cells [49].  
5.5 ROS induced cytoxicity independent of ceramide and autophagy 
In human pancreatic cancer cells, FEN-induced cytotoxicity appears to be mediated by 
ROS, but not by ceramide, since antioxidants and autophagy inhibitors (but not de novo 
ceramide inhibitor myriocin) blocked FEN-induced LC3 II expression and partially inhibited 
cell death [50]. Asumendi and co-workers found similar results in leukemia cells, suggesting 
that the two hallmarks of FEN-mediated cell death are independent mechanistic events [51].  
5.6 ROS, DJ-1, ASK1, p38 apoptosis pathway 
Interestingly, FEN-induced activation of the c-Jun N-terminal kinase (JNK) and p38 
MAPK in several cancer cell lines has been shown to be suppressed by antioxidants. 
Moreover, FEN-induced apoptosis is decreased by down regulating JNK or p38 MAPK 
activity using chemical inhibitors or small interfering RNAs [21]. JNK and p38 MAPK are 
activated by a wide range of cellular stresses including ROS. Recent findings in Hela cells 
have now implicated DJ-1, a multifunctional oxidative stress response protein and the ASK-1-
p38 MAPK pathway to regulate the balance between autophagy and apoptosis depending on 
the relative concentration of FEN and subsequent level of ROS generation [22]. ASK1-
mediated activation of JNK and p38 were found to be responsible for the FEN-induced 
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autophagy or apoptosis, respectively. However, the mildly oxidised form of DJ-1 (in the 
presence of a low FEN concentration) was found to bind to and inhibit ASK1 activation of 
p38 and thus inhibit FEN-induced apoptosis (via ROS generation). Moreover, this promoted 
FEN-induced autophagy and cell survival. Increasing the FEN concentration to induce high 
levels of ROS caused excessive DJ-1 oxidation and dissociation from ASK1, leading to p38 
activation and apoptosis. Promisingly, DJ-1 depletion in vivo with shRNA enhanced the 
sensitivity of tumor cells to FEN [22]. 
5.7 Hypoxia and HIF-1alpha 
Hypoxia induces resistance to many forms of anti-cancer therapy including FEN 
[52,53]. Moreover, under hypoxic conditions, FEN-induced autophagy appears to be hypoxia-
inducible factor (HIF)-1-α dependant and not inhibited by antioxidants [54].  Knockdown of 
HIF-1α inhibited autophagy but promoted 4-HPR-induced apoptosis suggesting an alternative 
strategy to overcome resistance to FEN-induced anti-cancer activity. There is a considerable 
body of evidence now, independent of studies with FEN, that implicates autophagy as a 
mostly cytoprotective mechanism and that it rarely, if ever, constitutes a lethal effector 
mechanism that is responsible for cell death [55]. 
5.8 MIC-1/PLAB/ NAG-1/ GDF-15 
To identify novel genes contributing to its apoptotic activity in ovarian cancer cells, 
transcriptome profiling was performed in human ovarian carcinoma cells and human 
umbilical vein endothelial cells. Macrophage inhibitory cytokine-1 (MIC-1), a proapoptotic 
and antiangiogenic gene, was the most highly induced [56,57]. MIC-1 levels were highly 
associated with FEN-induced apoptosis in several cell lines and were also induced in ascitic 
cells collected from patients with ovarian cancer before and after FEN treatment., The ER 
stress inhibitor salubrinal and the antioxidant vitamin C, abrogated 4HPR-induced activation 
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of JNK, MIC-1 up-regulation and protected the cells from apoptosis [58]. These results 
indicate a role for MIC-1 as a mediator of FEN-induced apoptosis at least in certain ovarian 
cancer cell lines.  MIC-1 encodes a protein sharing homologies with members of the 
transforming growth factor (TGF)-β superfamily and is also known as non-steroidal anti-
inflammatory drug-activated gene-1 (NAG-1), PLAcental Bone morphogenetic protein 
(PLAB), placental-TGFβ, prostate-derived factor (PDF) and growth differentiation factor-15 
(GDF-15). Studies with transgenic mice expressing human MIC-1 demonstrated that 
increased MIC-1 levels can inhibit the development of some tumors in animal models. 
However, contrasting laboratory and clinical evidence suggests that MIC-1 probably has 
diverse functions in carcinogenesis [59]. Interestingly, tumor-induced anorexia and weight 
loss may be partly mediated by overproduction of MIC-1 by tumors [60] (see following 
sections on the regulation of glucose and lipid homeostasis by FEN).  
The high level of cross-talk between these signalling intermediates has to date made it 
extremely difficult to elucidate exactly which genes and pathways are required for FEN‟s 
biological activities. ROS-mediated stress kinase activation appears to be central to FEN-
induced apoptosis where the novel discoveries regarding DHODH and DJ-1 may be critical 
missing links. In contrast, inhibition of DES1 leading to elevations in dihydroceramide levels 
is probably cytoprotective via promotion of autophagy pathways. The multiple signalling 
pathways involved in FEN-mediated anti-cancer activity in particular RAR-independent 
mechanisms of FEN-induced apoptosis are summarised in Fig. 2. 
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6. Regulation of glucose and lipid homeostasis by FEN. 
6.1 Lowering of circulating levels of RBP4 and retinol levels. 
In the first FEN human anti-cancer trials, FEN treatment was found to induce a 
decrease of plasma retinol, which was associated with an impaired adaptation to dark [17]. 
This side-effect could be minimized with a 3-day treatment interruption per month to increase 
plasma retinol concentrations and partial recovery of retinoid storage. This initial finding has 
contributed to one of the characteristic effects of FEN treatment, to lower the circulating 
levels of the specific retinol transport protein RBP4 [61]. RBP4, is primarily synthesised in 
the liver but also adipose tissue. Its primary function is to transport retinol (hydrolysed from 
stored retinyl esters) to supply peripheral tissues via tight binding to this specific serum 
transport protein [7,62]. Due to its small size (21 kDa), the retinol-RBP4 complex is prone to 
glomerular filtration but binding with another serum protein transthyretin prevents its loss 
from the circulation. FEN has a high binding affinity for RBP4 and thus can disrupt the 
complex [61]. FEN has been shown to form a tight association with RBP4 and the FEN-RBP4 
complex has been detected by immunoprecipitation [29,61]. FEN therefore maintains the 
ability to bind RBP4, but due to the presence of the bulky 4-hydroxyphenyl group, the 
protein-protein interaction between RBP4 and TTR is prevented from forming. Confirmation 
that this occurs was provided when the FEN-RBP4 complex obtained from treating the human 
hepatoma cell line (HepG2) with FEN, displayed a decrease in binding to a TTR affinity 
column [63]. Thus, by preventing the formation of the RBP4-TTR complex and increasing 
glomerular filtration after treatment with FEN, this leads to elevated levels of RBP4 in the 
kidney and urine and subsequently lowering of circulating levels of RBP4 and retinol [64]. It 
is this characteristic mechanism which first resulted in the application of FEN treatment to 
prevent insulin resistance associated with high-fat diet (HFD) feeding in mice. 
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In 2005, important findings originating from the laboratory of B.B. Kahn described 
the altered gene expression of RBP4 specifically from adipocytes and the negative 
contribution of elevated serum levels in the regulation of insulin sensitivity [65]. Elevated 
levels of this „adipokine‟ were found to associate with insulin resistance in multiple models of 
obesity and type II diabetes. FEN was identified as a potential pharmacological means of 
intervention and thus, by the mechanisms described above, FEN treatment provided an 
opportunity to decrease the elevated serum levels of RBP4 observed in HFD-induced states of 
obesity and insulin resistance. FEN decreased the elevated serum levels of RBP4 found in 
obese mice that had been fed a HFD, which subsequently led to improvements in insulin 
sensitivity [65]. These findings along with additional elegant experiments to genetically or 
pharmacologically increase circulating RBP4 levels provided evidence for a role for elevated 
RBP4 levels in impaired glucose homeostasis, which FEN was able to attenuate. It was 
reported in these initial investigations (which lasted for up to sixteen weeks in the FVB strain 
of mice), that FEN treatment did not affect food intake or bodyweight levels with HFD 
feeding. Importantly, since the discovery of FEN‟s additional beneficial effects in preventing 
insulin resistance in mice, it is also currently in a Phase-II clinical trials at the University of 
San Diego (California, USA) for the treatment of insulin resistance and liver inflammation 
related to non-alcoholic fatty liver in obese humans with results to be posted in early 2015. 
6.2 Mechanisms independent of RBP4 lowering. 
 A follow up examination provided detailed physiological evidence that the chronic 
treatment of mice with FEN was also able to partially prevent the onset of HFD-induced 
adiposity and obesity. These findings in FVB mice were apparent with the use of both a 
preventative and interventional approach [13]. Intriguingly, the beneficial anti-obesity effects 
observed with FEN treatment were entirely reproducible in mice lacking RBP4, i.e. 
genetically null animals (Rbp4
(-/-) 
mice) on the C57/129Sv mixed background, first described 
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by L. Quadro and colleagues [62]. This implied that the mechanism by which FEN functions 
to reduce body weight and adiposity was likely to be independent of the ability of FEN to 
reduce circulating levels of RBP4. Furthermore, not all models of obesity, insulin resistance 
or type II diabetes have reported elevations in circulating RBP4 levels however, technical 
problems using enzyme-linked immunoassays may undervalue elevated serum RBP4 
concentrations [66].   
6.3 Fen-induced RA-like effects on energy balance and glucose homeostasis 
Although it was documented that FEN could prevent the onset of HFD-induced gain 
in total body mass and more specifically fat mass, extensive examination revealed that FEN 
did not lead to measurable changes in food intake, energy expenditure, physical activity or 
stool lipid content [13,14].  Moreover, although RA also induces mitochondrial uncoupling 
protein (UCP)-1 in BAT to increase energy expenditure [67], FEN did not increase UCP1 
levels in BAT or WAT [14]. 
However, FEN did inhibit HFD-induced elevation in leptin serum levels and directly 
inhibited leptin mRNA in fully differentiated adipocytes [14]. Moreover, in a breast cancer 
clinical trial in premenopausal women, FEN improved insulin sensitivity and decreased serum 
leptin levels specifically in overweight women [68]. Leptin is released from adipocytes in 
postprandial states and acts as a satiety hormone via hypothalamic pathways to reduce food 
intake and increase energy expenditure. Leptin secretion is positively correlated with 
adiposity and therefore during states of obesity, circulating leptin levels are increased [69]. In 
obesity, this elevation is associated with loss of leptin-mediated action termed leptin 
resistance which ironically perpetuates obesity further. Interestingly, RA has been shown to 
decrease body weight and adiposity and to target leptin via decreases in WAT mRNA 
expression along with its secretion [67].  
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FEN-mediated alterations in adipose gene expression were not limited to leptin. FEN 
treatment prevented HFD-induced downregulation of peroxisome proliferator-activated 
receptor (Ppar)-γ, glucose transporter (Glut)-4 and adiponectin and lowered serum resistin 
and RBP4 levels [14]. Furthermore, both long term (20 weeks) and short term (7 days) FEN 
treatment lead to a marked induction in classic retinoid-responsive genes Crbp1, Rarβ and 
Cyp26a1 suggesting RAR-signalling was responsible for FEN‟s effects. 
Hepatic level of rate-limiting gluconeogenic enzyme phosphoenolpyruvate 
carboxykinase (PEPCK) is hormonal regulated during fasting and feeding. PEPCK is also 
induced with RA or RBP4 treatment [65,70] or decreased with substantially impaired RA 
synthesis in retinaldehyde dehydrogenase (RALDH)-1 knockout mice [71]. These studies 
strongly support retinoid nuclear receptor-mediated effects on PEPCK as a key determinant of 
hepatic gluconeogenesis and glucose intolerance associated with obesity and insulin 
resistance. However in contrast, euglycemic-hyperglycemic clamp studies in HFD-obese 
mice, FEN treatment completely normalised suppression of hepatic glucose production by 
insulin in association with improved whole body and skeletal muscle glucose uptake [13]. 
These findings imply that FEN-induced RAR-signalling in liver does not lead to induction of 
PEPCK and increased levels hepatic gluconeogenesis with HFD-induced obesity in vivo.  
Normalisation of HFD-induced hyperglycemia with FEN treatment maybe partly 
through central/hypothalamic effects of improved leptin sensitivity on the regulation of 
hepatic glucose production via the autonomic nervous system [13,14,72]. Interestingly, 
central administration of orexigenic neuropeptide Y (NPY) has been shown induce hepatic 
insulin resistance and RA can downregulate NPY in neuroblastoma cells [73,74]. Thus, a 
second possible central mechanism for the improved glucose homeostasis could be via direct 
suppression of NPY expression in the hypothalamus of FEN-treated mice [14].  
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As discussed earlier (section 5.8), MIC-1 was identified by transcriptome profiling of 
ovarian carcinoma cells as highly induced by FEN and associated with FEN-induced 
apoptosis in several cell lines [57]. Thus, FEN-induced MIC-1 up-regulation may mediate 
some of the anti-obesity effects of FEN treatment since overproduction of MIC-1 by tumors 
has been reported to contribute to tumor-induced anorexia and weight-loss in mice [60]. 
These studies identified MIC-1-signalling via hypothalamic TGFβ receptor II, ERK1/2 and 
signal transducer and activator of transcription (STAT)-3 led to up-regulation of POMC 
anorexigenic and downregulation of NPY orexigenic pathways, similar to the pattern 
observed with weight-loss in leptin-treated animals. However, it is not currently known if 
MIC-1 is induced by FEN in obesity models. 
While there are studies supporting an anti-adiposity action and overall beneficial 
effect of RA on metabolic profile, including changes in hepatic lipid metabolism leading to 
repartitioning of fatty acids away from triacylglycerol storage and towards oxidation, retinoid-
induced hypertriglyceridemia is a relatively frequent side effect of retinoid therapy (e.g. for 
dermatological disorders) [67]. Retinoid-induced hypertriglyceridemia in humans has also 
been modelled in a number of rodent studies and has been reported to occur in response to 
high doses of vitamin A (as retinol or retinyl palmitate), RA isomers (including RA, 9-cis RA 
and 13-cis RA), and synthetic RXR-specific agonists (rexinoids) [67]. Importantly, FEN-
treatment decreased severe hepatic steatosis by 50% in HFD-obese mice and did not increase 
circulating triglycerides, free-fatty acids or glycerol [13,14]. 
6.4 RA-signalling inhibits adipocyte differentiation. 
Adipogenesis is a complex and temporally regulated signalling cascade, which 
generates the machinery required in order for adipocytes to take up substrates for the 
synthesis and safe storage of lipids as triacylglycerols [75]. Confluent pre-adipocyte 
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(fibroblast-like) cell cultures can be synchronously induced to differentiate with an 
adipogenic “cocktail” stimulating glucocorticoid, cyclic-AMP and insulin-signalling. 
Numerous transcription factors are then induced and participate during the programme that is 
instrumental for terminal differentiation to occur. The most well-characterised of these are 
members of the CAAT/enhancer-binding protein (C/EBP) family of transcription factors, 
C/ebp beta and C/ebp delta which are induced early and transiently during adipocyte 
differentiation. Followed by induction of two intermediate and crucial regulators of 
adipogenesis, C/EBPα and PPARγ, of which PPARγ is the key master regulator of 
adipogenesis.  
Consistent with the findings that alterations to the retinol metabolism pathway play an 
important role in the regulation of adiposity, it has been well established that RA-RAR 
signalling is able to inhibit pre-adipocyte models of adipogenesis [76,77]. Detailed 
experimental evidence has revealed that the ability of RA to inhibit adipocyte differentiation 
is temporal, with RA inhibition only being achieved when supplemented within twenty-four 
hours of initiation of adipocyte differentiation [76,78]. This loss of RA inhibition occurs due 
to the downregulation of RARs, which is observed during adipocyte differentiation [78]. 
Consistent with this view, the RA window of inhibition can be extended up to forty-eight 
hours with the overexpression of RAR subtypes. However, after this time it appears adipocyte 
conversion reaches an irreversible check point where RA is no longer able to have an effect 
[78]. Additionally, the inhibition of adipocyte differentiation by RA was shown to be caused 
by the prevention of C/EBPβ mediated transcriptional activation [79]. In these studies, RA did 
not block the transcriptional induction of C/ebp beta, but inhibited its downstream induction 
of PPARγ and C/EBPα, which subsequently prevented expression of terminal adipocyte 
markers and the conversion of pre-adipocytes into mature lipid laden cultures. Results 
obtained in our lab, suggest that FEN acts similarly to RA in 3T3-L1 cells by blocking 
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adipogenesis via inhibition of C/EBPβ-mediated transcription of PPARγ, C/EBPα and 
subsequently expression of terminal adipocyte markers [14].  
Members of the AP1 family of transcription factors are induced immediately after the 
induction of adipocyte differentiation. RA can also downregulate the transcriptional activation 
of AP1 [80] and therefore may prevent early cell cycle events during the induction of the 
adipogenic transcription cascade. In transrepression assays in Hela cells co-transfected with 
RARs, a relatively high concentration of FEN (20 μM) was also found to be a potent inhibitor 
of AP1, suggesting another target of FEN-mediated inhibition of adipogenesis [31]. 
Further investigations have indicated that RA does not directly prevent C/EBPβ-
mediated transcriptional itself, but does so through increasing levels of a transcription factor 
from the mothers against decapentaplegic homolog (SMAD) family. Increased levels of 
SMAD3 were shown to interact with C/EBPβ and interfere with its ability to occupy the 
C/EBPα promoter. Moreover, in the absence of SMAD3, RA is no longer able to inhibit 
adipocyte differentiation [81]. It is currently unknown if FEN can also alter SMAD3 levels.  
RA or FEN-treatment leads to marked up-regulation of Crbp1 in adipocytes and in 
carcinoma cells [14,35]. Interestingly, in Crbp1
(-/-)
 mouse embryonic fibroblasts differentiated 
into adipocytes, or 3T3-L1 adipocytes where CRBP1 had been knocked down revealed 
increased triacylglyceride accumulation due to increased expression and activity of PPARγ. 
The overexpression of CRBP1 in 3T3-L1 cultures resulted in significantly reduced levels of 
triacylglyceride compared to controls [82]. These results suggest that CRBP1 can either 
directly influence PPARγ activity or do so indirectly by regulating retinoid homeostasis and 
RAR-signalling. 
6.5 Involvement of the non-canonical retinoid signalling pathway. 
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Noy and co-workers have shown that adipocyte differentiation is accompanied by 
downregulation of RAR and CRABP-II and upregulation of PPARβ/δ and FABP5. 
Consequently, whereas in preadipocytes RA functions predominantly through CRABP-II and 
RAR, the hormone signals through both pathways in the mature adipocytes [83]. Multiple 
studies established that RA treatment results in weight loss and enhances insulin sensitivity in 
various mouse models of obesity [83,84]. These effects can be traced, at least in part, to 
enhanced fatty acid oxidation and energy dissipation brought about by RA-induced activation 
of PPARβ/δ and RAR in mature adipocytes, liver, and skeletal muscle [83,85]. It is not 
currently known whether FEN can signal via PPARβ/δ. 
6. 6 Induction of apoptosis as a potential mechanism. 
 The extensive investigation of FEN has largely been due to the early discovery that it 
displayed favourable properties as a chemopreventive agent for breast cancer [11,17]. 
Subsequent studies revealed that FEN was able to attenuate uncontrolled cell proliferation in 
multiple cancer cell lines through the induction of apoptosis [21]. Seeing as FEN accumulates 
in fatty tissue and prolonged treatment prevents HFD-induced adiposity, it could be 
hypothesised that FEN may lead to the induction of adipocyte apoptosis and thereby lead to 
decreased adiposity. Through mechanisms that are not well established, FEN is able to cause 
apoptosis in cancerous transformed cells but not in normal cells which are unaffected by 
similar concentrations of FEN treatment [21]. Consistent with the view that FEN does not 
induce apoptosis in non-transformed cells, no alteration in the number of subcutaneous-WAT 
adipocytes was found in both the preventive and interventional studies, where FEN 
completely prevented subcutaneous-WAT mass expansion [13]. Although not conclusive 
evidence, these findings indicate that FEN is unlikely to cause apoptosis in developed adipose 
tissue and alternative mechanisms are therefore expected to be involved. Reports of hypoxia 
and HIF1α up-regulation in obesity [86] may actually protect adipocytes from FEN-induced 
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apoptosis, similar to the mechanism of hypoxia-induced resistance to anti-cancer therapy 
(section 5.7). 
6.7 Potential RAR-independent mechanisms of Fenretinide. 
 Interestingly, preventing ceramide lipid species accumulation may provide an 
alternative RAR-independent mechanism by which FEN operates to prevent the negative 
effects of HFD feeding on glucose and lipid regulation. Increased ceramide synthesis in 
response to excessive glucocorticoids, saturated free fatty acids or tumour necrosis factor 
(TNF)-α is associated with an inhibition of insulin signal transduction by promoting the 
dephosphorylation of Akt/PKB by protein phosphatase 2A (PP2A) and by blocking the 
activation and translocation of Akt/PKB from the cytoplasm to the plasma membrane [87,88]. 
Moreover, inhibition of ceramide synthesis improves glucose homeostasis in rodent models of 
obesity and insulin resistance. Specifically, genetic knockout of DES1, or treatment with de 
novo ceramide inhibitor myriocin improves glucose tolerance in rats [89]. In association with 
improved skeletal muscle and hepatic insulin sensitivity in vivo, myriocin pretreatment 
lowered ceramide levels and improved insulin action at the level of Akt/PKB. Thus, from 
these studies it could be concluded that ceramide-induced inactivation of Akt/PKB is a 
contributing mechanism by which the sphingolipid impairs insulin action [89]. 
Thus, by altering rates of cellular ceramide production at the level of DES1, FEN has been 
shown to prevent lipid induced insulin resistance in both cultured myotubes and isolated 
muscle strips [90]. Additionally, it was observed in vivo that increases in dihydroceramide 
levels were present in HFD fed mice treated with FEN incorporated into the drinking water. 
These alterations were associated with improvements in glucose homeostasis [90]. In these 
studies, FEN was found not to have an effect on adiposity. It is currently unknown if FEN 
also alters dihydroceramide levels in adipose tissue, which could be mechanistically 
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responsible for the beneficial outcomes when mice are supplemented with FEN in background 
of obesity. Since FEN exposure and dihydroceramide accumulation can initiate autophagy 
induction, FEN-mediated increases in dihydroceramide levels may activate a potential RAR-
independent mechanism of FEN action in vivo. 
Defective autophagy has been shown to play a role in hepatic insulin resistance during 
states of obesity [91]. Furthermore, autophagy appears to be involved in pancreatic beta-cell 
compensation during periods of HFD feeding [92]. The role of defective autophagy in adipose 
tissue has not been an area extensively investigated and so its function is currently unclear. 
Obese individuals for example have increased markers of autophagy in adipose tissue [93], 
which has led to the speculation that increased levels of adipose tissue autophagy may 
facilitate adipocyte enlargement [94]. Other studies however suggest that hypertrophic 
adipocytes display increased levels of autophagy due to the accumulation of autophagosomes 
that have not been appropriately processed due to reduced autophagic flux [95]. Whether FEN 
is able to alter levels of autophagy in adipose tissue has not been investigated to date. This 
however could provide an additional mechanism by which FEN modulates in order to inhibit 
adipose expansion and the development of insulin resistance in mice. The pathways proposed 
to play a role in FEN-mediated improvements in whole body metabolic homeostasis are 
summarised in Fig. 3. 
7. Conclusions and future directions. 
The mechanism of FEN action to induce apoptosis in cancer models and to prevent diet-
induced obesity and insulin resistance in mice has been under investigation for the last 20 
years or so. The pathways involved include ROS and dihydroceramide generation and the 
activation of stress kinases and autophagy (summarised in Fig. 2). Although the RAR-
dependant effects of FEN have been largely ignored by the cancer field for the last 10 years, 
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the growing interest in vitamin A as a modulator of body fat mass and glucose homeostasis 
has highlighted nuclear hormone receptor signalling as important once again in mediating at 
least some of the beneficial actions of FEN (summarised in Fig. 3). How these pathways may 
interact in different tissues, in different disease models and under various experimental 
conditions remains to be elucidated. The exact mechanism of altered nuclear hormone 
signalling (particularly in adipose tissue) to induce these beneficial actions also remains an 
unanswered question. However, given the safe toxicological profile of this synthetic retinoid, 
it would appear to be of relatively high clinical importance to continue to investigate the 
mechanism(s) of FEN action in specific cells, tissues and at the whole organism level. 
Delineating these should provide further rationale for improving the efficacy of FEN action to 
(1) induce apoptosis in cancerous tissues, (2) prevent obesity or (3) improve glucose 
homeostasis in obesity and type-2 diabetes. This may be in synergy with other 
chemotherapeutics or anti-obesity/diabetic regimens or through the development of improved 
analogues of FEN. 
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Figure legends 
 
Fig. 1. The chemical structure of all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide. 
FEN is identical to RA except for the modification to the carboxyl functional group, which is 
replaced with an amide linked 4-hydroxyphenyl group. 
 
Fig. 2. Signalling pathways proposed for FEN-induced apoptosis or cell survival. Refer to 
main text in sections 4 and 5 and [21] for details. Abbreviations: RAR, retinoic acid receptor; 
RARE, retinoic acid response element; Nurr77, a.k.a. nuclear receptor subfamily 4, group A, 
member 1 (NR4A1) or orphan nuclear receptor T3 (TR3); Bcl-2, B-cell CLL/lymphoma 2, 
founding member of the apoptosis regulator proteins; OXPHOS, oxidative phosphorylation; 
DHODH, dihydroorotate dehydrogenase; ROS, reactive oxygen species; PERK, protein 
kinase activated by double-stranded RNA (PKR)-like endoplasmic reticulum kinase; eIF2α, 
eukaryotic initiation factor 2α; CHOP, CCAAT-enhancer-binding protein (C/EBP) 
homologous protein also known as growth arrest and DNA damage-inducible gene 153 
(GADD153); BAK, BCL2-antagonist/killer; DJ-1, multifunctional oxidative stress response 
protein a.k.a. Parkinson disease protein 7 (PARK7); IRE1, inositol-requiring enzyme 1; 
ASK1, apoptosis signal-regulating kinase 1; p38, mitogen-activated protein kinase (MAPK) 
family member; JNK c-Jun N-terminal kinase; MIC-1, macrophage inhibitory cytokine-1 
a.k.a. non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1), PLAcental Bone 
morphogenetic protein (PLAB), placental-TGFβ, prostate-derived factor (PDF) and growth 
differentiation factor-15 (GDF-15); DES-1 dihydroceramide desaturase 1 is the final step of 
de novo synthesis of ceramide lipid species; Akt, a.k.a. protein kinase B (PKB); HIF-1α, 
hypoxia-inducible factor 1α; mTOR, mammalian target of rapamycin. 
 
Fig. 3. Molecular pathways proposed for FEN-mediated improvements in whole body 
metabolic homeostasis. Refer to main text in section 6 for details. The exact mechanism of 
altered nuclear hormone signalling (particularly in adipose tissue) to induce these beneficial 
actions remains a major unanswered question (marked by ? in the figure). Abbreviations: 
RAR, retinoic acid receptor; RARE, retinoic acid response element; PPARγ, peroxisome 
proliferator-activated receptor γ; C/EBPα, CCAAT-enhancer-binding protein α; RBP4, serum 
retinol binding protein; GLUT4, glucose transporter 4; NPY, neuropeptide Y; DES-1 
dihydroceramide desaturase 1 is the final step of de novo synthesis of ceramide lipid species; 
Akt, a.k.a. protein kinase B (PKB). 
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Fig. 1. The chemical structure of all-trans-retinoic acid and 
N-(4-hydroxyphenyl)retinamide. FEN is identical to RA 
except for the modification to the carboxyl functional 
group, which is replaced with an amide linked 4-
hydroxyphenyl group. 
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